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SUMMARY
Introduction Local therapy of denture stomatitis (DS) associated with Candida species fungi infection usually involves 
the application of nystatin and miconazole. Due to the fact that these drugs may be less efficient against biofilm and 
possible resistance development, a new approach in the treatment includes the use of antiseptic agents. 
The aim of the study was to compare clinical and microbiological therapeutic outcomes of antiseptic solution Listerine® 
and Daktanol® antifungal oral gel in the treatment of DS associated with Candida species fungi.
Material and Methods The study included 30 patients affected by DS, divided into the two treatment groups, control 
group (n=15) treated by Daktanol® gel and experimental group (n=15) treated by the antiseptic solution Listerine®. Suc-
cessful treatment was evaluated based on palatal mucosa inflammation reduction classified according to the Newton 
classification and the difference in the number of fungal colony- forming units (CFU) isolated by smears before and 
after the treatment that lasted 14 days.
Results Reduction in inflammation intensity and fungal CFU number on palatal mucosa (p<0,01) as well as on denture 
base (p<0,01) were observed in both groups of subjects after the treatment.
Conclusion Antiseptic solution Listerine® and Daktanol® antifungal gel both reduced palatal mucosal inflammation 
and CFU number of fungi in mouth without significant differences among them. CFU number of fungi isolated from 
denture base was significantly lower after the treatment with Listerine® (p<0.05).
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INTRODUCTION
Denture stomatitis (DS) is an inflammation of oral mu-
cosa covered by the denture base with reported incidence 
of 15-70% [1]. It is linked to a number of non-infectious 
aetiologies such as poor quality of dentures, poor hygiene 
and nocturnal denture wearing as well as infectious etio-
logical factor, Candida species fungi [2]. Number of fungal 
cells in the saliva and on dentures is leading etiological 
factor for DS development [3]. The degree of Candida al-
bicans (C.albicans) denture base contamination is directly 
correlated to inflammation intensity [4]. 
This disease is characterized by erythema of oral mu-
cosa covered by the denture base; it is usually asymptom-
atic and often associated with angular cheilitis [5]. Its 
intensity is clinically evaluated according to the Newton 
classification criteria [6,7]. DS treatment most frequently 
includes local and systemic administration of antifungals, 
reduction and eradication of biofilm, change of bad habits 
related to nocturnal denture wearing and poor denture 
hygiene as well as replacement of inadequate dentures. 
The most frequently used local antifungal drugs in dental 
practice are nystatin and miconazole [8,9]. Although ef-
fectively act against fungi, these drugs have no effect on 
biofilm matrix, therefore well-protected pathogens can 
survive in extracellular matrix. Also, their use comes with 
the risk of resistance development [10, 11]. Commercially 
available oral antiseptic Listerine® acts directly against 
fungal cell, chemically, causing damage to the cell wall 
structure and membrane permeability. Also, it disrupts 
metabolic processes dependant on microorganism mem-
brane enzymes, and, as other phenolic products, exerts 
anti-inflammatory effect [12]. Listerine® acts against free 
unbound Candida cells as well as against formed biofilm 
and it is shown to be more efficient than the azole anti-
fungal drugs [13]. This Listerine® solution property has 
not been studied in a clinical trial yet.
The aim of this study was to compare clinical and mi-
crobiological outcomes of antiseptic agent Listerine® and 
antifungal Daktanol® gel in the treatment of DS associated 
with Candida species fungi.
MATERIAL AND METHODS 
This prospective clinical study was conducted at the De-
partment of Dental Medicine in Foca and the Microbio-
logical laboratory of the University Hospital Foca. The 
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research was conducted in accordance with the principles 
of the Helsinki Declaration of 2008. Prior to inclusion in 
the study subjects were informed about the aim and the 
protocol of research and gave their consent to participa-
tion. The study included 30 patients, maxillary acrylic 
dentures wearers, affected by DS. Criteria for inclusion of 
patients in the study were good general health, or chronic 
well-controlled disease and dental acrylic dentures wear-
ing for at least one year. Also, swabs of palatal mucosa 
and denture basal surface had to be positive on Candida 
species fungi. Exclusion criteria were as follows: the use 
of corticosteroids and immunosuppressive therapy, tu-
mours of the maxillofacial region and radiotherapy in the 
head and neck area, chemotherapy in the last year, blood 
disorders, local surgical therapy in the last 3 months, lo-
cal or systemic use of antibiotics and antifungal drugs in 
the last 3 months, the use of hormones for therapeutic 
purposes, the existence of other diseases in the oral cavity 
and also functionally, prophylactically and cosmetically 
inadequate dentures that are indicated for replacement 
with new dentures.
By the means of random numbers table, participants 
who joined the study under even-number were classified 
into the control group and received standard treatment 
with Daktanol® oral gel (2% miconazole, Galenika a.d. 
Belgrade, Serbia). The participants included in the study 
under odd-number were classified into the experimental 
group and were treated with antiseptic agent Listerine® 
cool mint TM (Johnson&Johnson, S.p.A. Rome, Italy). Each 
group consisted of 15 patients, and therapy was adminis-
tered according to the following protocol:
1. Control group of patients (n = 15) received standard 
local antifungal therapy in the form of Daktanol® gel con-
taining 2% miconazole, used at the dose of 1-2 teaspoons, 
4 times per day for 14 days. Basal surface of dentures were 
coated with gel overnight and rinsed with water in the 
morning prior to use.
2. Experimental group of patients (n = 15) used an an-
tiseptic agent Listerine® also for 14 days as follows: 4 times 
a day 1 minute long mouth swish with antiseptic solution 
that was spitted afterward. Dentures were immersed in 
this solution overnight with base facing upward in a glass 
container, and completely overflowed by the Listerine® so-
lution. In the morning dentures were rinsed with water.
Parameters used for the evaluation of inflammation 
and denture contamination, as well as the presence of ex-
pected improvement were clinical and microbiological. 
Clinical improvement implied palatal mucosa inflamma-
tion intensity reduction after the treatment compared to 
the inflammation intensity prior to the therapy.
1. Clinical parameters
The intensity of palatal mucosa inflammation was as-
sessed by Newton classification which distinguishes three 
clinical types of denture stomatitis [6,7]: type Newton I: 
dotted hyperaemic shape and size of a pinhead lesion 
(pin-point) that present localized areas of poorly ex-
pressed inflammation; type Newton II: diffuse erythema 
of palatal mucosa covered by the denture base – general-
ized inflammation; type Newton III: granular surface of 
the mucosa- inflammatory papillary hyperplasia.
2. Microbiological parameters
Swabs of palatal mucosa surfaces and denture bases were 
taken without prior mouth and dentures rinsing, in the 
morning, before any food intake. Sabouraud dextrose 
agar was used to grow fungi and it was incubated at 37 
° C, for 48 hours. The number of fungal colonies (CFU-
colony forming units) was counted after 48 hours. The 
following criteria were used for CFU quantification: <10 
colonies present after incubation – smear is negative; 10-
25 colonies present after incubation – fungi present in 
small numbers; >25 colonies present after incubation – 
fungi are present in large numbers [14]. Two days after 
the treatments, control examinations were conducted and 
swabs for samples cultivation were taken again.
The obtained data were statistically analyzed in the 
SPSS software (SPSS for Windows, version 11.5, Chicago, 
Ill.). Description of the sample was carried out by descrip-
tive statistics methods. Therapeutic results within a group 
(paired samples) were evaluated by the Wilcoxon Signed 
Rank test. The effect of the therapy on the clinical im-
provement was assessed using the Fisher’s Exact Test, and 
therapeutic results between observed groups were com-
pared using χ² test. The relationship between certain char-
acteristics and inflammation intensity as well as therapy 
outcomes were estimated using χ² test and Fisher’s Exact 
Test. Results are presented in tables.
RESULTS
The study included 30 patients, 19 (63.3%) female and 
11 (36.7%) male, with an average age of 56.1 years (SD = 
7.126). The largest number of dentures, 17 (56.7%), was 
between 5 and 10 years old, 9 dentures (30%) were aged 
over 10 years, while 4 dentures (13.3%) were used less than 
5 years. Most of patients, 27 (90%) had clinically present 
denture stomatitis classified as type II Newton, while 3 pa-
tients (10%) had denture stomatitis Newton type III.
In both groups, significant reduction in the CFU num-
ber at the palate (p <0.01) as well as at the denture base 
was observed after the treatments (p <0.01) (Table 1).
Inflammation intensity reduction was observed in 
most patients, but significant difference after treatments 
between the two applied therapeutic modalities was not 
observed (Table 2). There was no significant difference 
in palate smear CFU number reduction in relation to the 
applied therapy, but significant difference (p <0.05) was 
observed in denture smear CFU number reduction in pa-
tients treated with antiseptic agent Listerine® compared to 
patients treated by Daktanol® oral gel (Table 3).
Gender, age of patients or age of dentures, had no sta-
tistically significant effect on clinical improvement after 
the treatment, as well as on the reduction in the CFU 
numbers isolated from palatal mucosa and denture basal 
surface after the treatment (Table 4)
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DISCUSSION
The present study evaluated the effect of oral antiseptic 
Listerine® on palatal mucosa inflammation and Candida 
species CFU number isolated from palatal mucosa and 
denture base among denture wearers affected with DS.
Literature review couldn’t identify other similar clini-
cal studies. Yet, there are indirect evidences of Listerine® 
antifungal properties that justify its use in DS treatment. 
Meiller et al. conducted an in vitro study in which they 
observed the effect of Listerine® on clinically isolated Can-
dida species, British and American strains of the same 
species. Fungal cells were incorporated into an experi-
mental biofilm. Authors reported that after 60 seconds of 
experimental biofilm exposure to this antiseptic, no living 
fungal cells were observed in the sample [15]. In a study 
conducted with clinically isolated Candida species, Lis-
terine® showed very good antimicrobial activity in labo-
ratory testing. After 60 minutes, there was no living cell 
of Candida species in the sample [16]. Listerine® was also 
efficient against experimental biofilm composed of one 
laboratory and 34 clinically isolated C. albicans strains 
where it reduced metabolical activity of fungi for 75-80% 
[13]. The effect of Listerine® against C.albicans clinical iso-
lates was confirmed in a recent study where Listerine® re-
duced C.albicans growth on Sabouraud dextrose agar [17]. 
The results presented in this study clinically confirmed 
findings of previous in vitro studies.
In the present study, Listerine® showed better efficacy 
in reducing the number of CFU isolated from denture 
basis compared to the Daktanol® gel. This finding could be 
the result of different viscosity of used agents. Miconazole 
was applied in a form of gel, what might hinder its denture 
base coating. However, due to its physical caracteristics, 
Listerine® solution, could reach rugged, porous acrylic sur-
face more easily. Beside therapy, improved hygiene and 
avoiding nocturnal dentures wearing could have positive 
impact on palatal mucosa inflammation reduction.
CONCLUSION
Therapeutic outcomes after the use of antiseptic agent 
Listerine® in DS treatment are similar to the therapeutic 
outcomes obtained by standard Daktanol® oral gel therapy. 
Therefore, Listerine® can be used in the treatment of DS 
associated with Candida species. 
Table 4. Influence of gender, age of respondents and age of dentures on the treatment outcome
Tabela 4. Uticaj pola, starosti ispitanika i starosti proteza na ishod terapije
Clinical improvement
Kliničko poboljšanje
Reduction of CFU in palate smear
Smanjenje CFU izolovanih u brisu nepca
Reduction of CFU in denture base smear

























Table 1. Reduction of isolated fungal colony forming unit (CFU) 
number after the treatment 
Tabela 1. Smanjenje broja izolovanih gljivičnih kolonija nakon za-
vršene terapije 
CFU number before and 
after the treatment














Povećan broj CFU 0 0 0 0
Decreased CFU number
Smanjen broj CFU 15 15 14 15
Unchanged CFU
Nepromenjen CFU 0 0 1 0







Paired sample, Wilcoxon Signed Rank test  
Vezani uzorak, Vilkoksonov test ekvivalentnih parova
Table 2. The influence of applied treatments on the clinical im-
provement
Tabela 2. Efikasnost primenjenog tretmana na kliničko poboljšanje
Clinical improvement
Kliničko poboljšanje




Da 11; 60.0 13;  86.7 24;  80.0
No
Ne 4;  40.0 2;  13.3 6;  20.0
Total
Ukupno 15;  100.0 15;  100.0 30;  100.0
Fisher’s Exact Test =0.241 
Fišerov test tačne verovatnoće =0,241
Table 3. Reduction of fungal colonies number isolated from palate 
and denture base after the treatment
Tabela 3. Efikasnost primenjenih terapija na smanjenje broja glji-
vičnih kolonija izolovanih sa nepca i baze proteze nakon terapije
Reduction of the number of 
fungal colonies
Smanjenje broja gljivičnih 
kolonija
Applied treatment





Da 9; 60.0% 12; 80.0% 21; 70.0%
Partially
Delimično 5; 33.3% 3; 20.0% 8; 26.7%
No




Da 8; 53.3% 14; 93.3% 22; 73.3%
Partially
Delimično 7; 46.7% 1; 6.7% 8; 26.7%
No
Ne 0; 0.0% 0; 0.0% 0; 0.0%
 *χ² = 1.929; df = 2; p = 0.381
** χ² = 6.136; df = 1; p = 0.013
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KRATAK SADRŽAJ
Uvod Lokalna terapija proteznog stomatitisa (PS) udruženog sa infekcijom gljivicama iz roda Candida najčešće se sprovodi upo-
trebom nistatina i mikonazola. Zbog otežanog dejstva ovih lekova na biofilm, kao i zbog razvoja moguće rezistencije, pažnja se 
usmerava na terapijske efekte koji se mogu postići primenom antiseptičkih sredstava. 
Cilj rada je da se uporede klinički i mikrobiološki ishodi primene antiseptičkog rastvora Listerine® i oralnog gela sa antimikotskim 
dejstvom Daktanol® u lečenju PS udruženog sa pojavom gljivica iz roda Candida.
Metode rada Studija je uključivala 30 ispitanika obolelih od PS, podeljenih u dve terapijske grupe: kontrolnu (n = 15) lečenu gelom 
Daktanol® i eksperimentalnu (n = 15) – antiseptikom Listerine®. Uspešnost terapije procenjivana je na osnovu smanjenja intenziteta 
zapaljenja palatinalne sluzokože procenjenog prema klasifikaciji Newton pre početka lečenja i razlike u broju brisom izolovanih 
gljivičnih kolonija (CFU) pre i posle terapije, koja je trajala 14 dana.
Rezultati Kod obe grupe ispitanika došlo je do smanjenja intenziteta zapaljenja i smanjenja CFU i na nepcu (p < 0,01) i na bazi 
proteze (p < 0,01) nakon terapije. 
Zaključak Antiseptički rastvor Listerine® i antimikotik Daktanol® dovode do smanjenja intenziteta zapaljenja palatinalne sluzokože i 
do značajnog smanjenja CFU u terapiji PS, bez međusobno značajne razlike, osim u smanjenju broja CFU izolovanih sa baze proteza 
nakon terapije, gde je rastvor Listerine® pokazao veću efikasnost (p < 0,05).
Ključne reči: Candida albicans; protezni stomatitis; Listerine, Daktanol gel
UVOD
Protezni stomatitis (PS) jeste zapaljenje oralne sluzokože po-
krivene bazom proteze sa prijavljenom učestalošću od 15 do 
70% [1]. Povezan je sa brojnim neinfektivnim etiološkim fak-
torima kao što su loš kvalitet proteza, slaba higijena i noćno 
nošenje nadoknada, kao i sa infektivnim etiološkim faktorom, 
gljivicama iz roda Candida [2]. Broj gljivičnih ćelija u pljuvač-
ki i na samim protezama igra vodeću ulogu u razvoju PS [3]. 
Stepen kontaminacije baze proteze gljivicom Candida albicans 
(C. albicans) u direktnoj je korelaciji sa intenzitetom zapaljenja 
palatinalne sluzokože [4].
Oboljenje karakteriše eritem onih područja oralne sluzokože 
koja su pokrivena bazom proteze, često je udruženo sa angu-
larnim heilitisom i najčešće je asimptomatsko [5]. Intenzitet 
oboljenja se klinički procenjuje klasifikacijom Newton [6, 7]. 
Terapija najčešće obuhvata lokalnu i sistemsku primenu antimi-
kotika, redukciju i eradikaciju biofilma, promenu loših navika 
vezanih za noćno nošenje i slabu higijenu proteza, te zamenu 
postojećih proteza ukoliko su neadekvatne. Dva najčešće prime-
njivana lokalna antimikotika u stomatološkoj praksi su nistatin 
i mikonazol [8, 9]. Iako efikasno deluju na gljivice, ovi lekovi ne-
maju uticaj na sam matriks biofilma, te dobro zaštićeni patogeni 
u ekstracelularnom matriksu mogu preživeti, a moguć je i razvoj 
rezistencije [10, 11]. Komercijalno dostupan oralni antiseptik 
Listerine® na gljivičnu ćeliju deluje direktno, hemijski, dovode-
ći do oštećenja strukture ćelijskog zida i poremećaja kontrole 
permeabiliteta membrane. Takođe, prekida metaboličke procese 
koji zavise od enzima prisutnih u membrani mikroorganizma, 
te kao i ostali fenolni preparati ispoljava antiinflamatorno dej-
stvo [12]. Listerine® deluje i na slobodne nevezane ćelije Can-
dide, kao i na formirani biofilm i to sa većom efikasnošću od 
azolnih antimikotika [13]. Ova dejstva rastvora Listerine® do 
sada nisu ispitivana u kliničkim uslovima.
Cilj rada bio je da se uporede klinički i mikrobiološki is-
hodi primene antiseptičkog sredstva Listerine® i antimikotika 
Daktanol® u lečenju PS udruženog sa pojavom gljivica iz roda 
Candida.
MATERIJAL I METODE RADA
Ova prospektivna klinička studija sprovedena je na Klinici za 
stomatologiju Medicinskog fakulteta u Foči i u Mikrobiološkoj 
laboratoriji Univerzitetske bolnice Foča. Istraživanje je sprovede-
no u skladu sa principima Helsinške deklaracije iz 2008. godine, 
a pre uključivanja u studiju ispitanici su bili upoznati sa ciljem 
i protokolom istraživanja i dali svoju saglasnost za učestvovanje 
u istom. Studija je obuhvatala 30 ispitanika, nosilaca gornjih to-
talnih akrilatnih proteza, obolelih od proteznog stomatitisa. Kri-
terijumi za uključivanje ispitanika u studiju bili su dobro opšte 
zdravstveno stanje, odnosno dobro kontrolisano opšte oboljenje 
i nošenje totalne proteze bar jednu godinu. Takođe, brisevi pa-
latinalne sluzokože i bazalne površine proteze morali su biti po-
zitivni na gljivice iz roda Candida. Kriterijumi za isključenje bili 
su sledeći: upotreba kortikosteroida i imunosupresivna terapija, 
tumori maksilofacijalne regije, zračna terapija u predelu glave i 
vrata, primenjena hemoterapija u poslednjoj godini dana, krvne 
diskrazije, lokalna hirurška terapija u protekla tri meseca, lokalna 
ili sistemska upotreba antibiotika i antimikotika u poslednja tri 
meseca, upotreba hormona u terapijske svrhe, postojanje drugog 
oboljenja u usnoj duplji, te neadekvatne proteze čija je funkcio-
nalna, profilaktička i estetska vrednost ugrožena u tolikoj meri 
da je indikovana izrada novih nadoknada.
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Pomoću tablice slučajnih brojeva određeno je da se ispitanici 
koji su se u studiju priključili pod parnim rednim brojem svr-
staju u kontrolnu grupu i primaju standardnu terapiju oralnim 
gelom Daktanol®  (2% mikonazol, Galenika a.d. Beograd, Srbija). 
Ispitanici uključeni u studiju pod neparnim rednim brojem svr-
stani su u eksperimentalnu grupu i primili su terapiju antisep-
tičnim sredstvom Listerine® cool mintTM (Johnson & Johnson, 
S.p.A. Rim, Italija). Svaka grupa se sastojala od po 15 ispitanika, 
a terapija je primenjivana po sledećem protokolu:
1. kontrolna grupa ispitanika (n = 15) primala je standardnu 
lokalnu antifungalnu terapiju u vidu gela Daktanol®, koji sadrži 
2% mikonazola, u dozi od 1-2 kafene kašičice, četiri puta dnev-
no, tokom 14 dana. Proteze su se preko noći sa bazalne strane 
premazivale gelom, a ujutro ispirale vodom pre upotrebe. 
2. eksperimentalna grupa ispitanika (n = 15) koristila je 
antiseptično sredstvo Listerine® i to po sledećem režimu: četiri 
puta dnevno jednominutno mućkanje antiseptičnog rastvora, 
koji se nakon tog vremena ispljune, a proteze su preko noći 
potapali u ovaj rastvor tako što su ih postavljali u čašu, bazom 
okrenutom ka gore i prelivali rastvorom Listerine® do potpunog 
prekrivanja svih njenih površina. Ujutro su se proteze ispirale 
vodom, a terapija je takođe trajala 14 dana.
Parametri na osnovu kojih se procenjivao stepen inflamacije 
i kontaminacije nadoknada, kao i nastupanje očekivanog po-
boljšanja, bili su klinički i mikrobiološki. Kliničko poboljšanje 
podrazumevalo je smanjenje intenziteta zapaljenja sluzokože 
nakon terapije u odnosu na intenzitet utvrđen pre terapije.
1. Klinički parametri
Intenzitet zapaljenja palatinalne sluzokože procenjivao se kla-
sifikacijom Newton, prema kojoj razlikujemo tri klinička tipa 
proteznog stomatitisa [6, 7]: tip Newton I – tačkaste hipere-
mične lezije oblika i veličine glave čiode koje predstavljaju lo-
kalizovana područja slabo izraženog zapaljenja; tip Newton II 
– difuzni eritem cele nepčane sluznice koja je pokrivena bazom 
proteze – generalizovano zapaljenje; te tip Newton III – granu-
larna površina mukoze – zapaljenska papilarna hiperplazija.
2. Mikrobiološki parametri
Uzimanje brisa inflamatorno promenjene nepčane sluzokože i 
bazne površine proteze vršeno je ujutro, natašte, bez prethodnog 
ispiranja usne šupljine i proteza, sterilnim štapićem vate. Mate-
rijal se zasijavao na saburo dekstrozni agar i inkubirao na 37°C, 
48 časova, nakon čega su utvrđivani prisustvo i broj gljivičnih 
kolonija. Da bi se kvantifikovao broj gljivičnih kolonija (CFU 
– colonie forming units), korišćeni su sledeći kriterijumi: <10 
kolonija nakon inkubacije – bris je negativan; 10–25 kolonija 
prisutnih nakon inkubacije – gljivice prisutne u manjem broju 
i >25 kolonija prisutnih nakon inkubacije – gljivice prisutne 
u većem broju [14]. Dva dana nakon isteka terapije vršeni su 
kontrolni pregledi i ponovo su uzimani brisevi za kultivaciju 
uzoraka.
Dobijeni podaci su statistički obrađeni u SPSS programu 
(SPSS za Windows, verzija 11.5, Chicago, Ill.). Opis uzorka 
vršen je metodama deskriptivne statistike. Terapijski rezulta-
ti unutar jedne grupe (vezani uzorak) procenjeni su pomoću 
Vilkoksonovog testa ekvivalentnih parova. Uticaj terapije na 
kliničko poboljšanje procenjen je primenom Fišerovog testa 
tačne verovatnoće, a terapijski rezultati između ispitivanih 
grupa poređeni su pomoću χ² testa. Povezanost pojedinih obe-
ležja sa intenzitetom zapaljenja i ishodom terapije procenjen je 
pomoću χ² testa i Fišerovog testa tačne verovatnoće. Rezultati 
su prikazani tabelarno.
REZULTATI
U studiju je bilo uključeno 30 ispitanika, 19 (63,3%) ženskog 
i 11 (36,7%) muškog pola, prosečne starosti 56,1 godina (SD 
= 7,126). Najveći broj proteza – 17 (56,7%) bio je star između 
pet i deset godina, devet proteza (30%) bile su stare više od 
deset godina, dok su četiri proteze (13,3%) korišćene kraće od 
pet godina. Najveći broj pacijenata – 27 (90%) imao je klinički 
izražen protezni stomatitis klasifikovan kao tip Newton II, dok 
su tri pacijenta (10%) imala protezni stomatitis tipa Newton III.
Kod obe grupe ispitanika došlo je do visoko značajnog sma-
njenja broja CFU i na nepcu (p < 0,01) i na bazi proteze nakon 
terapije (p < 0,01) (Tabela 1).
Smanjenje intenziteta zapaljenja nastupilo je kod većine ispi-
tanika, bez uočenog postojanja značajne razlike nakon terapije 
između dva primenjena terapijska modaliteta (Tabela 2). Nije 
pronađena značajna razlika u smanjenju broja CFU dobijenih 
brisom nepca u odnosu na primenjenu terapiju, ali je nađena 
značajna razlika (p < 0,05) u smanjenju broja CFU izolovanih 
brisom baze proteze kod pacijenata lečenih antiseptičnim sred-
stvom Listerine® u odnosu na pacijente lečene oralnim gelom 
Daktanol® (Tabela 3). 
 Pol i starost pacijenata, kao ni starost proteza, nisu imali 
statistički značajnog uticaja na smanjenje intenziteta zapaljenja 
nakon terapije, kao ni na smanjenje CFU broja izolovanih sa 
palatinalne sluzokože i bazalnih površina proteza nakon terapije 
(Tabela 4).  
DISKUSIJA
U našoj studiji procenjivan je uticaj oralnog antiseptika Listeri-
ne® na stepen inflamacije palatinalne sluzokože i broj kolonija 
gljivica iz roda Candida na nepcu i proteznoj ploči kod nosilaca 
totalnih proteza obolelih od proteznog stomatitisa. 
Druge kliničke studije koje su koristile isti tretman, po istom 
ili sličnom protokolu kao u našem istraživanju, nisu nađene pre-
gledom literature. Ipak, postoje posredni dokazi o antifungal-
nom dejstvu ovog sredstva koji opravdavaju njegovu primenu u 
terapiji proteznog stomatitisa. Meiller i saradnici su sproveli in 
vitro studiju u kojoj je proučavano dejstvo antiseptika Listerine® 
na kliničke izolate iz roda Candida i britanske i američke labo-
ratorijske sojeve istog roda. Posmatrajući antimikrobno dejstvo 
na gljivične ćelije u sastavu eksperimentalnog biofilma, utvr-
đeno je da nakon 60 sekundi izlaganja ovom antiseptiku više 
nije bilo živih gljivičnih ćelija u uzorku [15]. U studiji u kojoj 
su uzorci mikroorganizama poticali od pacijenata sa Candida-
pozitivnim brisom oralne sluzokože, Listerine® je pokazao veo-
ma dobru antimikrobnu aktivnost u in vitro uslovima. Nakon 
60-minutnog izlaganja, u uzorku nije bilo živih ćelija C. albicans 
[16]. U studiji u kojoj je ispitivano dejstvo antiseptika Listerine® 
na biofilm sastavljen od jednog laboratorijskog i 34 klinički 
izolovana soja vrste C. albicans, utvrđeno je da je Listerine® re-
Janjić-Pavlović O. et al. The use of essential oils based antiseptic solution in the treatment of denture stomatitis
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dukovao postojeću metaboličku aktivnost gljivica za 75–80% 
[13]. Efekat sredstva Listerine® na kliničke izolate C. albicans 
u biofilmu laboratorijski je potvrđen i u skorijem istraživanju, 
gde je Listerine® inhibisao rast C. albicans na saburo agaru [17]. 
Rezultati prikazani u našem istraživanju klinički su potvrdili 
nalaze navedenih in vitro studija, što se ogleda u smanjenju bro-
ja brisom izolovanih gljivičnih kolonija sa nepca i baze proteza 
nakon terapije proteznog stomatitisa. 
Listerine® je u našoj studiji pokazao veću efikasnost u sma-
njenju broja gljivičnih kolonija izolovanih brisom baze proteze 
u odnosu na rezultat dobijen u kontrolnoj grupi. Na ovakav na-
laz je mogla uticati različita viskoznost primenjenih sredstava. 
Mikonazol je bio primenjen u formi gela, pa je samim tim teže 
oblagao površinu proteza. Listerine® je zbog fizičkih karakteri-
stika rastvora lakše dopirao do neravnih, poroznih prostora i 
mikropukotina koje su prisutne na akrilatnoj bazalnoj površi-
ni zubnih nadoknada, što je mogući uzrok pronađene razlike. 
Pored korišćene terapije, smanjenju inflamacije palatinalne 
sluzokože mogli su doprineti poboljšani higijenski režim usne 
duplje i proteza, kao i noćno nenošenje proteza. 
ZAKLJUČAK
Terapijski ishodi primene antiseptičkog sredstva Listerine® u 
lečenju proteznog stomatitisa slični su terapijskim ishodima 
dobijenim primenom standardne terapije oralnim gelom Dak-
tanol®. Oralni antiseptik Listerine® može se koristiti u terapiji 
proteznog stomatitisa udruženog sa pojavom gljivica iz roda 
Candida kod nosilaca totalnih akrilatnih proteza.
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